UTRN

Across TCGA pan-cancer cohorts, UTRN mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated UTRN data layer compared with 28 for mass-spec protein and 13 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher UTRN mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated UTRN expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, GBM, and LUAD are the cancer types where UTRN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.274	0.501	.010	9	view →
GBM	DFS	Median	All	0.262	0.476	.020	4	view →
LUAD	OS	Tertile	All	0.898	0.700	.038	2	view →
LSCC	OS	Median	II,III,IV	0.878	1.000	.014	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

UTRN–PDAC (OS)

Open the PDAC breakdown →